
A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCE ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. Section 329-14, Hawaii Revised Statutes, is amended as follows:

1. By amending subsection (b) to read:

"(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

- (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- (2) Acetylmethadol;
- (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers;
- (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl);
- (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);

H.B. NO. 1133

- 1 (6) Allylprodine;
- 2 (7) Alphacetylmethadol (except levo-alphacetylmethadol,
- 3 levomethadyl acetate, or LAAM);
- 4 (8) Alphameprodine;
- 5 (9) Alphamethadol;
- 6 (10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-
- 7 phenethylpiperidin-4-yl)-N-phenylbutanamide);
- 8 ~~[(10)]~~ (11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
- 9 phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-
- 10 2-phenylethyl)-4-(N-propanilido)piperidine);
- 11 ~~[(11)]~~ (12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 12 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 13 ~~[(12)]~~ (13) Benzethidine;
- 14 ~~[(13)]~~ (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-
- 15 phenylpropanamide), its optical isomers, salts, and
- 16 salts of isomers;
- 17 ~~[(14)]~~ (15) Betacetylmethadol;
- 18 ~~[(15)]~~ (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
- 19 phenethyl)-4-piperidinyl]-N-phenylpropanamide);
- 20 ~~[(16)]~~ (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-
- 21 2-phenethyl)-3-methyl-4-piperidinyl]-N-
- 22 phenylpropanamide);

H.B. NO. 1133

- 1 [~~(17)~~] (18) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-
- 2 (thiophen-2-yl)ethyl]piperidin-4-yl]-N-
- 3 phenylpropionamide);
- 4 [~~(18)~~] (19) Betameprodine;
- 5 [~~(19)~~] (20) Betamethadol;
- 6 [~~(20)~~] (21) Beta-methyl fentanyl (N-phenyl-N-(1-(2-
- 7 phenylpropyl)piperidin-4-yl)propionamide) (Other
- 8 name: [beta]-methyl fentanyl);
- 9 [~~(21)~~] (22) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-
- 10 4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-
- 11 phenyl fentanyl; 3-phenylpropanoyl fentanyl);
- 12 [~~(22)~~] (23) Betaprodine;
- 13 (24) Brorphine 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-
- 14 yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one;
- 15 [~~(23)~~] (25) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-
- 16 N-phenylbutyramide);
- 17 [~~(24)~~] (26) Clonitazene;
- 18 [~~(25)~~] (27) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-
- 19 yl)-N-phenylcyclopropanecarboxamide);
- 20 [~~(26)~~] (28) Dextromoramide;
- 21 [~~(27)~~] (29) Diampromide;
- 22 [~~(28)~~] (30) Diethylthiambutene;

H.B. NO. 1133

- 1 [~~(29)~~] (31) Difeno~~x~~in;
2 [~~(30)~~] (32) Dimenoxadol;
3 [~~(31)~~] (33) Dimepheptanol;
4 (34) 2',5'-dimethoxyfentanyl (N-(1-(2,5-
5 dimethoxyphenethyl)piperidin-4-yl)-N-
6 phenylpropionamide);
7 [~~(32)~~] (35) Dimethylthiambutene;
8 [~~(33)~~] (36) Dioxaphetyl butyrate;
9 [~~(34)~~] (37) Dipipanone;
10 [~~(35)~~] (38) Ethylmethylthiambutene;
11 (39) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-
12 1-yl)-N,N-diethylethan-1-amine) (Other
13 name: etazene);
14 [~~(36)~~] (40) Etonitazene;
15 [~~(37)~~] (41) Eto~~x~~eridine;
16 [~~(38)~~] (42) Fentanyl carbamate (ethyl (1-phenethylpiperidin-
17 4-yl) (phenyl) carbamate);
18 [~~(39)~~] (43) 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-
19 N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other
20 name: para-fluoroisobutyryl fentanyl);
21 [~~(40)~~] (44) 2'-fluoro ortho-fluorofentanyl (N-(1-(2-
22 fluorophenethyl)piperidin-4-yl)-N-(2-

H.B. NO. 1133

- 1 fluorophenyl)propionamide) (Other name: 2'-fluoro 2-
2 fluorofentanyl);
- 3 ~~[(41)]~~ (45) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
4 N-phenylfuran-2-carboxamide);
- 5 (46) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
6 phenylfuran-3-carboxamide);
- 7 ~~[(42)]~~ (47) Furethidine;
- 8 ~~[(43)]~~ (48) Hydroxypethidine;
- 9 (49) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-
10 4-yl)-N-phenylbutanamide);
- 11 ~~[(44)]~~ (50) Ketobemidone;
- 12 ~~[(45)]~~ (51) Levomoramide;
- 13 ~~[(46)]~~ (52) Levophenacylmorphane;
- 14 (53) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-
15 phenethylpiperidin-4-yl)propionamide);
- 16 (54) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-
17 (1-phenethylpiperidin-4-yl)isobutyramide);
- 18 ~~[(47)]~~ (55) Methoxyacetyl fentanyl (2-methoxy-N-(1-
19 phenethylpiperidin-4-yl)-N-phenylacetamide);
- 20 (56) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-
21 yl)piperazin-1-yl)butan-1-one);

H.B. NO. 1133

- 1 (57) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-
2 nitro-1H-benzimidazol-1-yl)ethan-1-amine);
3 [~~(48)~~] (58) 4'-methyl acetyl fentanyl (N-(1-(4-
4 methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
5 [~~(49)~~] (59) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-
6 4-piperidyl]-N-phenylpropanamide);
7 [~~(50)~~] (60) 3-methylthiofentanyl (N-[3-methyl-1-(2-
8 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
9 [~~(51)~~] (61) Morpheridine;
10 [~~(52)~~] (62) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
11 (63) N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-
12 benzimidazol-1-yl)ethan-1-amine (other name:
13 protonitazene);
14 (64) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-
15 1(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (other
16 name: etonitazepyne);
17 [~~(53)~~] (65) Noracymethadol;
18 [~~(54)~~] (66) Norlevorphanol;
19 [~~(55)~~] (67) Normethadone;
20 [~~(56)~~] (68) Norpipanone;
21 [~~(57)~~] (69) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
22 phenethylpiperidin-4-yl)acetamide];

H.B. NO. 1133

- 1 [~~(58)~~] (70) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-
2 N-(1-phenethylpiperidin-4-yl)acrylamide);
- 3 [~~(59)~~] (71) Ortho-fluorobutyryl fentanyl (N-(2-
4 fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
5 (Other name: 2-fluorobutyryl fentanyl);
- 6 (72) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-
7 phenethylpiperidin-4-yl)furan-2-carboxamide);
- 8 [~~(60)~~] (73) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-
9 phenethylpiperidin-4-yl)propionamide) (Other name: 2-
10 fluorofentanyl);
- 11 [~~(61)~~] (74) Ortho-fluoroisobutyryl fentanyl (N-(2-
12 fluorophenyl)-N-(1-phenethylpiperidin-4-
13 yl)isobutyramide);
- 14 [~~(62)~~] (75) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-
15 N-(1-phenethylpiperidin-4-yl)acetamide) (Other
16 name: 2-methyl acetylfentanyl);
- 17 [~~(63)~~] (76) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-
18 N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-
19 yl)acetamide) (Other name: 2-methyl methoxyacetyl
20 fentanyl);
- 21 [~~(64)~~] (77) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-
22 N-(1-phenethylpiperidin-4-yl)butyramide);

H.B. NO. 1133

- 1 ~~[(+65)]~~ (78) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
2 phenethyl)-4-piperidinyl]propanamide;
3 ~~[(+66)]~~ (79) Para-fluoro furanyl fentanyl (N-(4-
4 fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-
5 carboxamide);
6 (80) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-
7 (1-phenethylpiperidin-4-yl)furan-2-carboxamide);
8 (81) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-
9 (1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
10 ~~[(+67)]~~ (82) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-
11 phenethylpiperidin-4-yl)propionamide) (Other name: 4-
12 methylfentanyl);
13 ~~[(+68)]~~ (83) PEPAP (1-(-2-phenethyl)-4-phenyl-4-
14 acetoxypiperidine);
15 ~~[(+69)]~~ (84) Phenadoxone;
16 ~~[(+70)]~~ (85) Phenampromide;
17 ~~[(+71)]~~ (86) Phenomorphan;
18 ~~[(+72)]~~ (87) Phenoperidine;
19 ~~[(+73)]~~ (88) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-
20 N-phenylbenzamide) (Other name: benzoyl fentanyl);
21 ~~[(+74)]~~ (89) Piritramide;
22 ~~[(+75)]~~ (90) Proheptazine;

H.B. NO. 1133

- 1 [~~(76)~~] (91) Properidine;
- 2 [~~(77)~~] (92) Propiram;
- 3 [~~(78)~~] (93) Racemoramide;
- 4 [~~(79)~~] (94) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-
- 5 piperidyl]-N-phenylpropanamide), its optical isomers,
- 6 salts, and salts of isomers;
- 7 [~~(80)~~] (95) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
- 8 piperidinyl]-propanamide);
- 9 [~~(81)~~] (96) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-
- 10 yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-
- 11 thiofuranyl fentanyl; thiophene fentanyl);
- 12 [~~(82)~~] (97) Tilidine;
- 13 [~~(83)~~] (98) Trimeperidine; and
- 14 [~~(84)~~] (99) U-47700 (3,4-dichloro-N-[2-
- 15 (dimethylamino)cyclohexyl]-N-methylbenzamide."

16 2. By amending subsection (d) to read:

17 "(d) Hallucinogenic substances. Unless specifically
18 excepted or unless listed in another schedule, any material,
19 compound, mixture, or preparation that contains any quantity of
20 the following hallucinogenic substances, including their salts,
21 isomers, and salts of isomers, whenever the existence of these

H.B. NO. 1133

salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) Alpha-ethyltryptamine (AET);
- (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- (3) 2,5-dimethoxyamphetamine (2,5-DMA);
- (4) 3,4-methylenedioxy amphetamine;
- (5) 3,4-methylenedioxymethamphetamine (MDMA);
- (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);
- (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- (11) 3,4,5-trimethoxy amphetamine;
- (12) Bufotenine;
- (13) 4-methoxyamphetamine (PMA);
- (14) Diethyltryptamine;
- (15) Dimethyltryptamine;
- (16) 4-methyl-2,5-dimethoxy-amphetamine;
- (17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-

H.B. NO. 1133

- 1 hydroxybutanoic acid; sodium oxybate; sodium
- 2 oxybutyrate);
- 3 (18) Ibogaine;
- 4 (19) Lysergic acid diethylamide;
- 5 (20) Marijuana;
- 6 (21) Parahexyl;
- 7 (22) Mescaline;
- 8 (23) Peyote;
- 9 (24) N-ethyl-3-piperidyl benzilate;
- 10 (25) N-methyl-3-piperidyl benzilate;
- 11 (26) Psilocybin;
- 12 (27) Psilocyn;
- 13 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 14 (29) Ethylamine analog of phencyclidine (PCE);
- 15 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 16 (31) Thiophene analog of phencyclidine (TPCP; TCP);
- 17 (32) Gamma-butyrolactone, including butyrolactone;
- 18 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 19 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 20 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 21 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 22 lactone and 4-hydroxybutanoic acid lactone with

H.B. NO. 1133

- 1 Chemical Abstract Service number 96-48-0 when any such
- 2 substance is intended for human ingestion;
- 3 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;
- 4 1,4- butylenes glycol; butylene glycol; 1,4-
- 5 dihydroxybutane; 1,4- tetramethylene glycol;
- 6 tetramethylene glycol; tetramethylene 1,4- diol with
- 7 Chemical Abstract Service number 110-63-4 when any
- 8 such substance is intended for human ingestion;
- 9 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
- 10 its optical isomers, salts, and salts of isomers;
- 11 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its
- 12 optical isomers, salts, and salts of isomers;
- 13 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
- 14 optical isomers, salts, and salts of isomers;
- 15 (37) Alpha-methyltryptamine (AMT);
- 16 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 17 (39) Salvia divinorum;
- 18 (40) Salvinorin A;
- 19 (41) Divinorin A;
- 20 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
- 21 trade or other names: 5-methoxy-3-[2-
- 22 (dimethylamino)ethyl]indole; 5-MeO-DMT);

H.B. NO. 1133

- 1 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 2 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 3 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 4 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 5 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
- 6 2);
- 7 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
- 8 (2C-T-4);
- 9 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 10 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 11 (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 12 (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
- 13 methoxybenzyl)ethanamine, its optical, positional, and
- 14 geometric isomers, salts, and salts of isomers (Other
- 15 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
- 16 (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
- 17 methoxybenzyl)ethanamine, its optical, positional, and
- 18 geometric isomers, salts, and salts of isomers (Other
- 19 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
- 20 (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
- 21 methoxybenzyl)ethanamine, its optical, positional, and

H.B. NO. 1133

- 1 geometric isomers, salts, and salts of isomers (Other
2 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
- 3 (55) N-ethylhexedrone, its optical, positional, and
4 geometric isomers, salts, and salts of isomers (Other
5 names: [alpha]-ethylaminohexanophenone; 2-
6 (ethylamino)-1-phenylhexan-1-one);
- 7 (56) Alpha-pyrrolidinohexanophenone, its optical,
8 positional, and geometric isomers, salts, and salts of
9 isomers (Other names: [alpha]-PHP; [alpha]-
10 pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-
11 yl)hexan-1-one);
- 12 (57) 4-methyl-alpha-ethylaminopentiophenone, its optical,
13 positional, and geometric isomers, salts, and salts of
14 isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
15 methylphenyl)pentan-1-one);
- 16 (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical,
17 positional, and geometric isomers, salts, and salts of
18 isomers (Other names: MPHP; 4'-methyl-alpha-
19 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-
20 (pyrrolidin-1-yl)hexan-1-one);
- 21 (59) Alpha-pyrrolidinoheptaphenone, its optical,
22 positional, and geometric isomers, salts, and salts of

H.B. NO. 1133

- 1 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-
2 yl)heptan-1-one);
- 3 (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical,
4 positional, and geometric isomers, salts, and salts of
5 isomers (Other names: 4-chloro-[alpha]-PVP; 4'-
6 chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-
7 chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); [~~and~~]
- 8 (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one
9 (methoxetamine, MXE) [~~-~~];
- 10 (62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-
11 (ethylamino)butan-1-one) (other name: bk-EBDB); and
- 12 (63) Zipeprol (1-methoxy-3[-4-(2-methoxy-2-
13 phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol),
14 including its isomers, esters, ethers, salts, and
15 salts of isomers, esters and ethers, whenever the
16 existence of such isomers, esters, ethers and salts is
17 possible within the specific chemical designation."

18 3. By amending subsection (f) to read:

19 "(f) Stimulants. Unless specifically excepted or unless
20 listed in another schedule, any material, compound, mixture, or
21 preparation that contains any quantity of the following

H.B. NO. 1133

substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Amineptine;

~~[(1)]~~ (2) Aminorex;

~~[(2)]~~ (3) Cathinone;

~~[(3)]~~ (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR);

~~[(4)]~~ (5) Fenethylline;

(6) Mesocarb (chemical name: N-phenyl-N'-(3-(1-

phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-

yl) carbamimidate);

~~[(5)]~~ (7) Methcathinone;

(8) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-

amine);

~~[(6)]~~ (9) 4-methylaminorex;

~~[(7)]~~ (10) N-ethylamphetamine;

~~[(8)]~~ (11) N,N-dimethylamphetamine;

~~[(9)]~~ (12) Substituted cathinones, any compound, except

bupropion or compounds listed under a different

schedule, structurally derived from 2-aminopropan-1-

one by substitution at the 1-position with either

phenyl, naphthyl, or thiophene ring systems, whether

H.B. NO. 1133

1 or not the compound is further modified in any of the
2 following ways:

3 (A) By substitution in the ring system to any extent
4 with alkyl, alkylenedioxy, alkoxy, haloalkyl,
5 hydroxyl, or halide substituents, whether or not
6 further substituted in the ring system by one or
7 more other univalent substituents;

8 (B) By substitution at the 3-position with an acyclic
9 alkyl substituent; or

10 (C) By substitution at the 2-amino nitrogen atom with
11 alkyl, dialkyl, benzyl, or methoxybenzyl groups,
12 or by inclusion of the 2-amino nitrogen atom in a
13 cyclic structure.

14 Some other trade names: Mephedrone (2-methylamino-1-p-
15 tolylpropan-1-one), also known as 4-
16 methylmethcathinone (4-MMC), methylephedrone or MMCA;
17 Methylenedioxypyrovalerone (MDPV, MDPK); methylone or
18 3,4-methylenedioxymethcathinone; and 1-
19 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,
20 monohydrochloride, also known as Ethylone, bk-MDEA
21 hydrochloride, MDEC; 3,4-Methylenedioxy-N-
22 ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-

H.B. NO. 1133

1 methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-
2 pyrrolidinopropiophenone (4-MePPP); alpha-
3 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-
4 benzodioxol-5-yl)-2-(methylamino)butan-1-one
5 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-
6 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-
7 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-
8 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-
9 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-
10 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-
11 pyrrolidinobutiophenone ([alpha]-PBP) and their
12 optical, positional, and geometric isomers, salts and
13 salts of isomers, whenever the existence of such
14 salts, isomers, and salts of isomers is possible; and
15 ~~[-(10)]~~ (13) 1-(4-methoxyphenyl)-N-methylpropan-2-amine
16 (Other names: para-methoxymethamphetamine; PMMA)."

17 SECTION 2. Section 329-20, Hawaii Revised Statutes, is
18 amended to read as follows:

19 "§329-20 **Schedule IV.** (a) The controlled substances
20 listed in this section are included in schedule IV.

21 (b) Depressants. Unless specifically excepted or unless
22 listed in another schedule, any material, compound, mixture, or

H.B. NO. 1133

1 preparation that contains any quantity of the following
2 substances, including its salts, isomers, esters, ethers, and
3 salts of isomers, whenever the existence of these isomers,
4 esters, ethers, and salts is possible within the specific
5 chemical designation, that has a degree of danger or probable
6 danger associated with a depressant effect on the central
7 nervous system:

- 8 (1) Alprazolam;
- 9 (2) Barbitol;
- 10 (3) Brexanolone;
- 11 (4) Bromazepam;
- 12 (5) Butorphanol;
- 13 (6) Camazepam;
- 14 (7) Carisoprodol;
- 15 (8) Chloral betaine;
- 16 (9) Chloral hydrate;
- 17 (10) Chlordiazepoxide;
- 18 (11) Clobazam;
- 19 (12) Clonazepam;
- 20 (13) Clorazepate;
- 21 (14) Clotiazepam;
- 22 (15) Cloxazolam;

H.B. NO. 1133

- 1 (16) Daridorexant;
- 2 (17) Delorazepam;
- 3 (18) Diazepam;
- 4 (19) Dichloralphenazone (Midrin);
- 5 (20) Estazolam;
- 6 (21) Ethchlorvynol;
- 7 (22) Ethinamate;
- 8 (23) Ethyl loflazepate;
- 9 (24) Fludiazepam;
- 10 (25) Flunitrazepam;
- 11 (26) Flurazepam;
- 12 (27) Fospropofol (Lusedra);
- 13 (28) Halazepam;
- 14 (29) Haloxazolam;
- 15 (30) Ketazolam;
- 16 (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-
- 17 yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-
- 18 yl)cyclopropane-1-carboxamide);
- 19 (32) Loprazolam;
- 20 (33) Lorazepam;
- 21 (34) Lormetazepam;
- 22 (35) Mebutamate;

H.B. NO. 1133

- 1 (36) Medazepam;
- 2 (37) Meprobamate;
- 3 (38) Methohexital;
- 4 (39) Methylphenobarbital (mephobarbital);
- 5 (40) Midazolam;
- 6 (41) Nimetazepam;
- 7 (42) Nitrazepam;
- 8 (43) Nordiazepam;
- 9 (44) Oxazepam;
- 10 (45) Oxazolam;
- 11 (46) Paraldehyde;
- 12 (47) Petrichloral;
- 13 (48) Phenobarbital;
- 14 (49) Pinazepam;
- 15 (50) Prazepam;
- 16 (51) Quazepam;
- 17 (52) Remimazolam;
- 18 (53) Suvorexant;
- 19 (54) Temazepam;
- 20 (55) Tetrazepam;
- 21 (56) Triazolam;
- 22 (57) Zaleplon;

H.B. NO. 1133

1 (58) Zolpidem; [and]

2 (59) Zopiclone (Lunesta) [-] and

3 (60) Zuranolone.

4 [~~(c)~~ ~~Fenfluramine. Any material, compound, mixture, or~~
5 ~~preparation which contains any quantity of the following~~
6 ~~substances, including its salts, isomers, and salts of isomers,~~
7 ~~whenever the existence of such salts, isomers, and salts of~~
8 ~~isomers is possible: Fenfluramine.~~

9 ~~(d)]~~ (c) Stimulants. Unless listed in another schedule,
10 any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a stimulant
12 effect on the central nervous system, including its salts,
13 isomers, and salts of such isomers whenever the existence of
14 such salts, isomers, and salts of isomers is possible within the
15 specific chemical designation:

16 (1) Cathine ((+)-norpseudoephedrine);

17 (2) Diethylpropion;

18 (3) Fencamfamin;

19 (4) Fenproporex;

20 (5) Lorcaserin;

21 (6) Mazindol;

22 (7) Mefenorex;

H.B. NO. 1133

(8) Modafinil;

(9) Pemoline (including organometallic complexes and
chelates thereof);

(10) Phentermine;

(11) Pipradrol;

(12) Serdexmethylphenidate;

(13) Sibutramine;

(14) Solriamfetol; and

(15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine).

[+e+] (d) Other substances. Unless specifically excepted
or unless listed in another schedule, any material, compound,
mixture, or preparation which contains any quantity of the
following substances, including its optical isomers and its
salts, isomers, and salts of isomers:

(1) Pentazocine; and

(2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-
2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-
imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
acid.

[+f+] (e) The department of law enforcement may except by
rule any compound, mixture, or preparation containing any
depressant substance listed in subsection (b) or any stimulant

H.B. NO. 1133

1 listed in subsection [~~(d)~~] (c) from the application of all or
2 any part of this chapter if the compound, mixture, or
3 preparation contains one or more active medicinal ingredients
4 not having a depressant or stimulant effect on the central
5 nervous system, and if the admixtures are included therein in
6 combinations, quantity, proportion, or concentration that
7 vitiate the degree of danger or probable danger of the
8 substances which have a depressant or stimulant effect on the
9 central nervous system.

10 [~~(g)~~] (f) Narcotic drugs. Unless specifically excepted or
11 unless listed in another schedule, any material, compound,
12 mixture, or preparation containing any of the following narcotic
13 drugs, or their salts calculated as the free anhydrous base or
14 alkaloid, in limited quantities as set forth below:

- 15 (1) Not more than one milligram of difenoxin and not less
16 than twenty-five micrograms of atropine sulfate per
17 dosage unit;
- 18 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-
19 diphenyl-3-methyl-2-propionoxybutane); and
- 20 (3) 2-[(dimethylamino)methyl]-1-(3-
21 methoxyphenyl)cyclohexanol, its salts, optical and

H.B. NO. 1133

1 geometric isomers and salts of these isomers
2 (including tramadol)."

SECTION 3. Statutory material to be repealed is bracketed
and stricken. New statutory material is underscored.

5 SECTION 4. This Act shall take effect upon its approval.

INTRODUCED BY: Nashine K. Parker

8 BY REQUEST

JAN 21 2025

H.B. NO. 1133

Report Title:

Uniform Controlled Substances Act

Description:

Updates chapter 329, HRS, to make it consistent with amendments in the Federal Controlled Substances Act as required under section 329-11, HRS.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

JUSTIFICATION SHEET

DEPARTMENT: Law Enforcement

TITLE: A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

PURPOSE: To update chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments in the Federal Controlled Substances Act.

MEANS: Amend sections 329-14(b), (d), and (f) and 329-20, HRS.

JUSTIFICATION: Section 329-11, HRS, requires that the Department of Law Enforcement annually recommend changes to the Hawaii Uniform Controlled Substances Act to correspond with changes to the Federal Controlled Substances Act.

Impact on the public: This bill is intended to protect the public by updating Hawaii's controlled substance schedules consistent with federal law.

Impact on the department and other agencies: These proposed amendments would assist the Department's Narcotics Enforcement Division in clarifying regulations of the Uniform Controlled Substances Act.

GENERAL FUND: None.

OTHER FUNDS: None.

PPBS PROGRAM DESIGNATION: LAW 502.

OTHER AFFECTED AGENCIES: Department of Health Food and Drug Branch; federal, state, and county law enforcement agencies.

EFFECTIVE DATE: Upon approval.